Literature DB >> 12200646

Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children.

I Kocsis1, A Arató, H Bodánszky, L Szönyi, A Szabó, T Tulassay, B Vásárhelyi.   

Abstract

Gastric proton pump inhibitors are widely used in the treatment of dyspeptic problems and for the eradication of H. pylori infection. Data are not available on whether omeprazole, a representative of proton pump inhibitors, influences the function of osteoclastic H+-pump in children. We studied the impact of short-term omeprazole administration on the biochemical parameters of bone turnover in pediatric patients. Urinary calcium excretion, serum total alkaline phosphatase activity, collagen type 1 crosslinked C-telopeptide, and osteocalcin levels were determined in 34 children [20 girls (9 prepubertal) and 14 boys (6 prepubertal)] before and after 2 weeks of omeprazole treatment at a dose of 20 mg/day. The measured parameters were within the healthy reference range in each patient. None of them altered during the study in any age or in any gender. We conclude that omeprazole, at a dose of 20 mg/day, does not significantly influence the investigated biochemical parameters of osteoclast and osteoblast function in pediatric patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200646     DOI: 10.1007/s00223-001-2068-9

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  13 in total

1.  Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial.

Authors:  Matthew J Wright; Rebecca R Sullivan; Erin Gaffney-Stomberg; Donna M Caseria; Kimberly O O'Brien; Deborah D Proctor; Christine A Simpson; Jane E Kerstetter; Karl L Insogna
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

Review 2.  Potential adverse effects of proton pump inhibitors.

Authors:  Gregory A Coté; Colin W Howden
Journal:  Curr Gastroenterol Rep       Date:  2008-06

3.  Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.

Authors:  T N Poly; M M Islam; H-C Yang; C C Wu; Y-C J Li
Journal:  Osteoporos Int       Date:  2018-12-12       Impact factor: 4.507

4.  Safety profile of six months lansoprozole treatment in children.

Authors:  Makbule Eren; Selda Hekim Yıldırım; Ilknur Ak Sivrikoz
Journal:  Indian J Gastroenterol       Date:  2011-01-11

5.  Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.

Authors:  Elaine W Yu; Scott R Bauer; Paul A Bain; Douglas C Bauer
Journal:  Am J Med       Date:  2011-06       Impact factor: 4.965

Review 6.  Bone Health in Glomerular Kidney Disease.

Authors:  Dorey A Glenn; Michelle R Denburg
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

Review 7.  Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2010-12

8.  Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.

Authors:  S Pouwels; A Lalmohamed; P Souverein; C Cooper; B J Veldt; H G Leufkens; A de Boer; T van Staa; F de Vries
Journal:  Osteoporos Int       Date:  2010-06-29       Impact factor: 4.507

9.  Do proton pump inhibitors decrease calcium absorption?

Authors:  Karen E Hansen; Andrea N Jones; Mary J Lindstrom; Lisa A Davis; Toni E Ziegler; Kristina L Penniston; Amy L Alvig; Martin M Shafer
Journal:  J Bone Miner Res       Date:  2010-06-24       Impact factor: 6.741

10.  Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?

Authors:  Kristin M Aasarød; Mats P Mosti; Malin T Finstad; Astrid K Stunes; Reidar Fossmark; Unni Syversen
Journal:  Bone Rep       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.